Houston, United States
Lasergen, Inc. is an emerging biotechnology company founded in 2002, based in the United States. The company focuses on commercializing novel technologies for DNA sequencing and has gained recognition for its expertise in nucleotide chemistry and next-generation sequencing. Their key discoveries have led to the development of game-changing sequencing chemistry, Lightning Terminators™, and a more accurate sequencing platform.
Lasergen's commitment to innovation and extensive sequencing knowledge has attracted significant investment, with the latest being an $80.00M Series B investment led by Agilent Technologies on 07 March 2016. The investment reinforces the confidence of industry leaders in the company's cutting-edge technology and its potential to keep pace with the fast-changing advances in the sequencing industry.
The company operates in the Biotechnology and Health Care industries, positioning itself as a key player in the evolution of DNA sequencing technologies.
